These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35895603)

  • 1. Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
    Park S; Park SH; Byun YJ; Choi SA
    PLoS One; 2022; 17(7):e0270906. PubMed ID: 35895603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database.
    Park HT; Park S; Jung YW; Choi SA
    Diagnostics (Basel); 2022 Oct; 12(10):. PubMed ID: 36292123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
    Park S; Kim Y; Lee GH; Choi SA
    Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics for asthma and risk of pneumonia.
    Matera MG; Ora J; Calzetta L; Rogliani P; Cazzola M
    J Asthma; 2024 Sep; 61(9):905-911. PubMed ID: 38294705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
    Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
    Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
    Pera V; Brusselle GG; Riemann S; Kors JA; Van Mulligen EM; Parry R; de Wilde M; Rijnbeek PR; Verhamme KMC
    Front Pharmacol; 2023; 14():1276340. PubMed ID: 38035014
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
    Jackson K; Bahna SL
    Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
    [No Abstract]   [Full Text] [Related]  

  • 12. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
    Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
    Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System.
    Bian S; Zhang P; Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B; Chen Z
    Front Pharmacol; 2021; 12():767999. PubMed ID: 34744748
    [No Abstract]   [Full Text] [Related]  

  • 14. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.
    Park S; Lee JH; Park JH; Park SH; Park SY; Jung YW; Choi SA
    Sci Rep; 2021 Jul; 11(1):14293. PubMed ID: 34253801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive analysis on the safety of two biologics dupilumab and omalizumab.
    Xiao Y; Yang W; Wang M
    Front Med (Lausanne); 2024; 11():1435370. PubMed ID: 39175817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy of Dupilumab in Alopecia Areata.
    Kulkarni M; Rohan CA; Travers JB; Serrao R
    Am J Case Rep; 2022 Jun; 23():e936488. PubMed ID: 35726185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.